Semaglutide
593 RCTsFDA approved
| Produces clinically meaningful weight loss | supported |
| Improves glycaemic control in type 2 diabetes | supported |
| Free of side effects | overreach |
Goal matrix
Metabolic & fat loss
Every compound we track for this goal.
3 FDA approved1 Well researched2 Emerging4 Limited evidence
Tirzepatide
182 RCTsFDA approved
| Greater average weight loss than semaglutide | supported |
| Requires no medical supervision | overreach |
Tesamorelin
38 RCTsFDA approved
| Reduces visceral fat in HIV-associated lipodystrophy | supported |
| Produces general fat loss in healthy adults | weak evidence |
| Improves cognition in ageing | weak evidence |
Retatrutide
15 RCTsWell researched
| Largest weight loss of any trialled agent to date | partially true |
| Approved and available | overreach |
Cagrilintide
18 RCTsEmerging
| Promotes satiety through the amylin pathway | supported |
| Adds weight loss when combined with semaglutide | partially true |
| Proven as a standalone weight-loss therapy | weak evidence |
MOTS-c
7 RCTsEmerging
| Improves exercise capacity | animal data only |
| Regulates metabolism via mitochondrial signalling | preclinical only |
| Reverses metabolic disease in humans | overreach |
Tesamorelin / Ipamorelin blend
—Limited evidence
| Mechanistically complementary GH stimulation | partially true |
| Covered by tesamorelin regulatory approval | overreach |
Triple Threat blend
—Limited evidence
| Boosts energy and metabolism | weak evidence |
| Each component is clinically proven | overreach |
5-Amino-1MQ
0 RCTsLimited evidence
| Is a peptide | overreach |
| Shrinks fat cells | animal data only |
| Produces fat loss in humans | weak evidence |
AOD-9604
0 RCTsLimited evidence
| Burns fat without growth-hormone side effects | weak evidence |
| Failed to beat placebo in human trials | supported |
→